COVID-19: Developing Drugs and Biological Products for Treatment or Prevention: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 24, 2023
May 2, 2025
a6c3249b-9395-4d0b-96dd-986a992b4139
Related Documents
Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment : Guidance for Industry
Guidance DocumentFebruary 22, 2024Center for Drug Evaluation and Research
Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4 Guidance for Industry: Guidance for Industry
Guidance DocumentMarch 22, 2022Center for Drug Evaluation and Research
Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization
Guidance DocumentDecember 21, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox